SuperworthKodiak Sciences market cap KOD
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $5.5B
- Highest close in our data
- $7.4B
- Jan 2021
Kodiak Sciences is worth $5.5B at the close on Oct 23, 2026, at $87.63 a share.
That is up 458% over the last year and down 9% over five years.
Its highest close in our data was $7.4B in Jan 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $5.5B | $1.2B | $6.3B | +247% |
| 2025 | $1.6B | $115M | $1.6B | +202% |
| 2024 | $525.2M | $121.5M | $525.2M | +229% |
| 2023 | $159.5M | $74.5M | $479.1M | −57% |
| 2022 | $374.5M | $287.3M | $3.7B | −91% |
| 2021 | $4.4B | $4B | $7.4B | −33% |
| 2020 | $6.6B | $1.9B | $6.9B | +142% |
| 2019 | $2.7B | $239.4M | $2.7B | +1017% |
| 2018 | $243.1M | $224.7M | $368.3M | n/a |
Against its peers
Companies in Biotechnology nearest Kodiak Sciences' size, closest first, today.
| Company | Market cap |
|---|---|
| KODKodiak Sciences | $5.5B |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| Peer median | $12.8B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Kodiak Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.